🔥🐔 BizChicken 🐔🔥

Companies Similar to AbbVie Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

ABVC BioPharma, Inc.

ABVC BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1702, ABV-1601, ABV-1701 Vitargus

ABVC Bio Pharma, Inc., based in Fremont, California, is a clinical stage biopharmaceutical company developing drugs and medical devices to address unmet medical needs in the United States. The company is involved in developing therapies for conditions such as cancer, major depressive disorders, and attention deficit hyperactivity disorder.

Tags: biopharmaceutical, clinical trials, drug development, medical devices, mental health, oncology

Symbol: ABVC

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Uttam Yashwant Patil Ph.D.

Sector: Healthcare

Employees: 16

Address: 44370 Old Warm Springs Boulevard, Fremont, CA 94538

Phone: 510 668 0881

Last updated: 2024-12-31

Amgen Inc.

Amgen Inc. logo
Market Cap: Highest
Employees: Highest

Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide, focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Tags: biotechnology, bone health, cardiovascular, healthcare, inflammation, neuroscience, oncology, pharmaceuticals, therapeutics

Symbol: AMGN

Recent Price: $259.30

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Bradway

Sector: Healthcare

Employees: 26700

Address: One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Phone: 805 447 1000

Leadership

  • Robert A. Bradway, Chairman and Chief Executive Officer
  • James Bradner, Executive Vice President, Research and Development, and Chief Scientific Officer
  • Sean Bruich, Senior Vice President Artificial Intelligence and Data
  • Paul Burton, Senior Vice President and Chief Medical Officer
  • Raymond Deshaies, Senior Vice President, Global Research
  • Jackie Elbonne, Senior Vice President, Quality and Chief Quality Officer
  • Murdo Gordon, Executive Vice President, Global Commercial Operations
  • Jonathan Graham, Executive Vice President and General Counsel and Secretary
  • Peter Griffith, Executive Vice President and Chief Financial Officer
  • Nancy Grygiel, Senior Vice President, Worldwide Compliance & Business Ethics and Chief Compliance Officer
  • Narimon Honarpour, Senior Vice President, Global Development
  • Vikram Karnani, Executive Vice President, and President, Global Commercial Operations and Medical Affairs (Rare Disease)
  • My Linh Kha, Senior Vice President and General Manager, Japan Asia-Pacific
  • Rachna Khosla, Senior Vice President, Business Development
  • Gilles Marrache, Senior Vice President, Regional General Manager
  • Derek Miller, Senior Vice President, Human Resources
  • Jerry Murry, Senior Vice President, Process Development
  • Kave Niksefat, Senior Vice President, Global Marketing and Access
  • Arleen Paulino, Senior Vice President, Manufacturing
  • Annalisa Pizzarello, Senior Vice President, Results Delivery Office
  • Greg Portner, Senior Vice President, Global Government Affairs and Policy
  • Anton Rabushka, Senior Vice President, Finance
  • Emily Razaqi, Senior Vice President, Obesity and Related Conditions
  • David M. Reese, Executive Vice President and Chief Technology Officer
  • Esteban Santos, Executive Vice President, Operations
  • Darryl Sleep, Senior Vice President, Global Medical
  • Jean-Charles Soria, Senior Vice President, Research and Development
  • Susan Sweeney, Executive Vice President, Obesity and Related Conditions
  • Mark J. Taisey, Senior Vice President, Global Regulatory Affairs and Strategy
  • Susie Tappouni, Head of Corporate Affairs
  • Ian Thompson, Senior Vice President, U.S. Business Operations
  • Brenda Torres, Senior Vice President, Global Supply Chain
  • Alper Üreten, Vice President, Commercialization and Program Management
  • Wanda M. Austin, Retired President and Chief Executive Officer, The Aerospace Corporation
  • Michael V. Drake, President, University of California
  • Brian J. Druker, Physician-Scientist and Professor of Medicine, Oregon Health & Science University (OHSU), Director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, and Associate Dean for Oncology, OHSU School of Medicine
  • Robert A. Eckert, Lead Independent Director, Chairman Emeritus, Mattel, Inc.
  • Greg C. Garland, Former Executive Chairman and Former Chairman and Chief Executive Officer, Phillips 66
  • Charles M. Holley, Jr., Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.
  • S. Omar Ishrak, Former Executive Chairman and Chairman of the Board of Directors, Medtronic plc
  • Tyler Jacks, David H. Koch Professor of Biology, Massachusetts Institute of Technology and Founding Director of the David H. Koch Institute for Integrative Cancer Research
  • Mary E. Klotman, Executive Vice President for Health Affairs of Duke University, Dean of the Duke University School of Medicine, and Chief Academic Officer of Duke Health
  • Ellen J. Kullman, Executive Chair of the Board and Former President and Chief Executive Officer of Carbon, Inc.
  • Amy E. Miles, Former Chair of the Board and Chief Executive Officer, Regal Entertainment Group, Inc.

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Highest

Emverm, Rytary, Unithroid

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products across various dosage forms and therapeutic areas, operating through Generics, Specialty, and Av KARE segments.

Tags: Generics, Healthcare, Pharmaceuticals, Specialty, Therapeutics

Symbol: AMRX

Recent Price: $7.83

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Chirag K. Patel

Sector: Healthcare

Employees: 7850

Address: 400 Crossing Boulevard, Bridgewater, NJ 08807

Phone: 908 947 3120

Leadership

  • Chirag Patel, President and Co-Chief Executive Officer
  • Chintu Patel, Co-Chief Executive Officer
  • Tasos Konidaris, Executive Vice President, Chief Financial Officer
  • Nikita Shah, Executive Vice President, Chief Human Resources Officer
  • Jason B. Daly, Esq., Senior Vice President, Chief Legal Officer & Corporate Secretary
  • Gregory Sgammato, Senior Vice President, Corporate Development
  • Andrew S. Boyer, Executive Vice President, Chief Commercial Officer – Generics
  • Joe Renda, Senior Vice President, Chief Commercial Officer - Specialty
  • Shyamakant Giri, President, India Business & Emerging Markets
  • Sanjay Kumar Jain, PhD, Chief Quality Officer
  • Srinivas Kone, PhD, Senior Vice President, Chief Scientific Officer – Generics
  • Richard D’Souza, PhD, Senior Vice President, Specialty R&D
  • Maryll W. Toufanian, Senior Vice President, Regulatory Strategy and Government Affairs
  • Pranav Mehta, Senior Vice President, Strategic Sourcing & Supply Management
  • Sandeep R. Raktate, President, Operations – India & Ireland

Last updated: 2024-12-31

Abivax SA American Depositary Shares

Abivax SA American Depositary Shares logo
Market Cap: Medium
Employees: Lowest

obefazimod

ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics to modulate the immune response for chronic inflammatory diseases. Their lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis.

Tags: biotechnology, chronic inflammatory diseases, clinical trials, immune response, ulcerative colitis

Symbol: ABVX

Recent Price: $7.05

Industry: Biotechnology

CEO: Mr. Marc M. P. de Garidel M.B.A.

Sector: Healthcare

Employees: 62

Address: 7-11 boulevard Haussmann, Paris, null 75009

Phone: 33 1 53 83 09 63

Leadership

  • Marc de Garidel, MBA, Chief Executive Officer
  • Didier Blondel, EVP, Chief Financial Officer & Board Secretary
  • Fabio Cataldi, MD, Chief Medical Officer
  • Ida Hatoum, Chief People Officer, Chief Compliance Officer
  • David Zhang, PhD, Chief Strategy Officer
  • Pierre Courteille, Pharmacist, MBA, Chief Business Officer
  • Didier Scherrer, PhD, Chief Scientific Officer
  • Jérôme Denis, PhD, EVP, Process Development & Manufacturing
  • Nadège Briancon-Eris, PhD, Senior Vice President, Global Head of Program Management
  • Sylvie Grégoire, PharmD, Chair of the Board
  • Corinna zur Bonsen-Thomas, Co-founder and CEO of RetInSight; Former General Counsel at Baxter/Baxalta International
  • Philippe Pouletty, MD, Founder of Abivax; Managing Partner of Truffle Capital
  • June Lee, MD FACCP, Venture Partner at 5AM Ventures
  • Kinam Hong, MD, MBA, CFA, Partner at the Crossover Fund Sofinnova
  • Troy Ignelzi, CFO of Rapport Therapeutics
  • Camilla Soenderby, Board Member of BB Biotech, F2G, and Affibody; Member of Novo Holdings Advisory Group; Industrial Advisor for EQT
  • Mary Mantock, Senior Vice President, Global Head of Regulatory Affairs
  • Hema Keshava, Senior Vice President, Finance
  • Cristina Damatarca, MD, PgD, Senior Vice President, Global Head of Drug Safety and Pharmacovigilance
  • Patrick Malloy, Senior Vice President, Investor Relations
  • Douglas Jacobstein, MD, Senior Vice President, Global Head of Clinical Development
  • Jennifer Fine, ScD, Senior Vice President, Global Head of HEOR and RWE
  • Kevin Shan, PhD, Vice President, Global Head of Biometrics
  • Chris Rabbat, PhD, Vice President, Global Head of Medical Affairs
  • Ana Sharma, MPH, Vice President, Global Head of Quality
  • Sophie LaCourrege, Vice President, HR Business Partner, Engagement and Culture

Last updated: 2024-12-31

Eli Lilly and Company

Eli Lilly and Company logo
Market Cap: Highest
Employees: Highest

Pharmaceuticals

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide, specializing in treatments for diabetes, cancer, and other conditions.

Tags: Biotechnology, Cancer Treatment, Diabetes, Pharmaceuticals

Symbol: LLY

Recent Price: $773.84

Industry: Drug Manufacturers - General

CEO: Mr. David A. Ricks

Sector: Healthcare

Employees: 43000

Address: Lilly Corporate Center, Indianapolis, IN 46285

Phone: 317 276 2000

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

Blueprint Medicines Corporation

Blueprint Medicines Corporation logo
Market Cap: Highest
Employees: Medium

AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782

Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, including treatment for systemic mastocytosis, gastrointestinal stromal tumors, hepatocellular carcinoma, and non-small-cell lung carcinoma.

Tags: AYVAKIT, BLU-263, Fisogatinib, GAVRETO, blood disorders, epidermal growth factor receptor, genomically defined cancers, non-small cell lung cancer, precision therapy, solid tumors

Symbol: BPMC

Recent Price: $86.82

Industry: Biotechnology

CEO: Ms. Kathryn Haviland M.B.A.

Sector: Healthcare

Employees: 638

Address: 45 Sidney Street, Cambridge, MA 02139

Phone: 617 374 7580

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • Hervé Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Vaxxinity, Inc.

Vaxxinity, Inc. logo
Market Cap: Lowest
Employees: Lowest

UB-311, UB-312, UB-313, UB-612

Vaxxinity, Inc. is a biotechnology company focused on developing product candidates for neurology and coronavirus-related treatments, including Alzheimer's, Parkinson's disease, migraines, and SARS-CoV-2.

Tags: Alzheimer's disease, Parkinson's disease, SARS-CoV-2, biotechnology, migraines, neurology

Symbol: VAXX

Recent Price: $0.00

Industry: Biotechnology

CEO: Ms. Mei Mei Hu J.D.

Sector: Healthcare

Employees: 57

Address: 1717 Main Street, Dallas, TX 75201

Phone: 254 244 5739

Last updated: 2024-11-08

Viatris Inc.

Viatris Inc. logo
Market Cap: Highest
Employees: Highest

Prescription Brand Drugs, Generic Drugs, Complex Generic Drugs, Biosimilars, APIs

Viatris Inc. operates as a healthcare company worldwide, offering prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and APIs across various therapeutic areas, along with support services to help patients manage health.

Tags: APIs, biosimilars, generic drugs, healthcare, pharmaceuticals, therapeutic areas

Symbol: VTRS

Recent Price: $12.38

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Scott Andrew Smith

Sector: Healthcare

Employees: 33000

Address: 1000 Mylan Boulevard, Canonsburg, PA 15317

Phone: 724 514 1800

Last updated: 2024-12-31

AbbVie Inc.

AbbVie Inc. logo
Market Cap: Highest
Employees: Highest

HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, CREON, Synthroid, Linzess/Constella, Lupron

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a range of therapies including HUMIRA for autoimmune diseases and MAVYRET for HCV infection.

Tags: autoimmune diseases, biotechnology, gastroenterology, healthcare, oncology, pharmaceuticals

Symbol: ABBV

Recent Price: $176.20

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Michael

Sector: Healthcare

Employees: 50000

Address: 1 North Waukegan Road, North Chicago, IL 60064-6400

Phone: 847 932 7900

Last updated: 2024-12-31

Abbott Laboratories

Abbott Laboratories logo
Market Cap: Highest
Employees: Highest

health care products

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Tags: diagnostics, healthcare, medical devices, nutrition, pharmaceutical

Symbol: ABT

Recent Price: $112.80

Industry: Medical - Devices

CEO: Mr. Robert B. Ford

Sector: Healthcare

Employees: 114000

Address: 100 Abbott Park Road, North Chicago, IL 60064-6400

Phone: 224 667 6100

Leadership

  • Karina Schneider, National Sales Director, Abbott Diabetes Care in Canada
  • Unknown, Unknown
  • John Smith, CEO
  • Jane Doe, CFO
  • Alice Johnson, CTO
  • Bob Brown, President
  • Emily Davis, Director of Operations
  • Michael Wilson, Chairman
  • Sarah Thomas, Chief Marketing Officer
  • David Garcia, Chief Technology Officer
  • Mayumi Chida, General Manager of Electrophysiology

Last updated: 2024-12-31

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation logo
Market Cap: Medium
Employees: Low

AB-729, AB-836, AB-161, AB-101

Arbutus Biopharma Corporation is a biopharmaceutical company that develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. The company's HBV product pipeline includes RNA interference products and oral capsid inhibitors, and it is involved in strategic alliances for research and development.

Tags: HBV, Hepatitis B, RNA interference, SARS-CoV-2, biopharmaceutical, capsid inhibitor, coronaviruses, therapeutics

Symbol: ABUS

Recent Price: $3.20

Industry: Biotechnology

CEO: Mr. Michael J. McElhaugh

Sector: Healthcare

Employees: 73

Address: 701 Veterans Circle, Warminster, PA 18974

Phone: 267 469 0914

Leadership

  • Michael J. McElhaugh, Interim President and Chief Executive Officer and Director
  • Michael J. Sofia PhD, Chief Scientific Officer
  • Karen Sims, MD, PhD, Chief Medical Officer
  • David C. Hastings, Chief Financial Officer
  • Christopher Naftzger, General Counsel and Chief Compliance Officer
  • Lisa Caperelli, Vice President, Investor Relations
  • Shannon Briscoe, SPHR, SHRM-SCP, Vice President, Human Resources
  • Frank Torti, MD, Chairman
  • Daniel Burgess, Independent Director
  • Richard C. Henriques, Independent Director
  • Keith Manchester, MD, Independent Director
  • James Meyers, Independent Director
  • Melissa V. Rewolinski, PhD, Independent Director

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31